28th Jul 2006 12:00
Vernalis PLC28 July 2006 28 July 2006 Additional Listing Vernalis plc (LSE: VER, NASDAQ: VNLS) has made application to the UK ListingAuthority and to the London Stock Exchange for 1,837,271 Ordinary Shares of 5pence each ("Shares") to be admitted to the Official List and to be admitted totrading on the London Stock Exchange's market for listed securities (together,"Admission"). The applications are being made in respect of shares issued today (subject onlyto Admission becoming effective) as part of the consideration for theacquisition of Ionix Pharmaceuticals Limited ("Ionix") which was completed inJuly 2005. These Shares represent deferred consideration for that acquisitionand were subject to reduction for certain warranty or indemnity claims in the 12months following completion of the acquisition. No such claims have been madeand therefore the 1,837,271 Shares are now being allotted to Ionix shareholders.It is expected that Admission will occur at 8.00am on 1 August 2006. - ends - Enquiries: Vernalis plc +44 (0)118 977 3133Simon Sturge, Chief ExecutiveTony Weir, Chief Financial OfficerJulia Wilson, Head of Corporate Communications Brunswick Group +44 (0)20 7404 5959Jon ColesJustine McIlroy About VernalisVernalis is a speciality bio-pharmaceutical company focused on products marketedto specialist neurologists. The company has two marketed products, Frova(R) andApokyn(R), and a development pipeline focused on neurology and central nervoussystem disorders. The company has seven products in clinical development andcollaborations with leading, global pharmaceutical companies including Novartis,Biogen Idec and Serono. Vernalis has established a US commercial operation topromote Apokyn(R) and co-promote Frova(R) alongside its North American licensingpartner, Endo Pharmaceuticals, propelling the company towards its goal ofbecoming a sustainable, self-funding, R&D-driven, speciality bio-pharmaceuticalcompany. For further information about Vernalis, please visit www.vernalis.com. Vernalis Forward-Looking StatementThis news release may contain forward-looking statements that reflect theCompany's current expectations regarding future events including the clinicaldevelopment and regulatory clearance of the Company's products, the Company'sability to find partners for the development and commercialisation of itsproducts, as well as the Company's future capital raising activities.Forward-looking statements involve risks and uncertainties. Actual events coulddiffer materially from those projected herein and depend on a number of factorsincluding the success of the Company's research strategies, the applicability ofthe discoveries made therein, the successful and timely completion of clinicalstudies, the uncertainties related to the regulatory process, the ability of theCompany to identify and agree beneficial terms with suitable partners for thecommercialisation and/or development of its products, as well as the achievementof expected synergies from such transactions, the acceptance of Frova(R) andApokyn(R) and other products by consumers and medical professionals, thesuccessful integration of completed mergers and acquisitions and achievement ofexpected synergies from such transactions, and the ability of the Company toidentify and consummate suitable strategic and business combinationtransactions. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Vernalis PLC